

Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in *Mycobacterium tuberculosis*

Maha R. Farhat,^{a,b} Karen R. Jacobson,^{c,d} Molly F. Franke,^b Devinder Kaur,^e Alex Sloutsky,^e Carole D. Mitnick,^{b,f} Megan Murray^{b,g}

Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA^a; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA^b; Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts, USA^c; DST/NRF Centre of Excellence for Biomedical TB Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa^d; University of Massachusetts Medical School, Massachusetts Supranational TB Reference Laboratory, Boston, Massachusetts, USA^e; Department of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA^f; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA^g

Molecular diagnostics that rapidly and accurately predict resistance to fluoroquinolone drugs and especially later-generation agents promise to improve treatment outcomes for patients with multidrug-resistant tuberculosis and prevent the spread of disease. Mutations in the *gyr* genes are known to confer most fluoroquinolone resistance, but knowledge about the effects of *gyr* mutations on susceptibility to early- versus later-generation fluoroquinolones and about the role of mutation-mutation interactions is limited. Here, we sequenced the full *gyrA* and *gyrB* open reading frames in 240 multidrug-resistant and extensively drug-resistant tuberculosis strains and quantified their ofloxacin and moxifloxacin MIC by testing growth at six concentrations for each drug. We constructed a multivariate regression model to assess both the individual mutation effects and interactions on the drug MICs. We found that *gyrB* mutations contribute to fluoroquinolone resistance both individually and through interactions with *gyrA* mutations. These effects were statistically significant. In these clinical isolates, several *gyrA* and *gyrB* mutations conferred different levels of resistance to ofloxacin and moxifloxacin. Consideration of *gyr* mutation combinations during the interpretation of molecular test results may improve the accuracy of predicting the fluoroquinolone resistance phenotype. Further, the differential effects of *gyr* mutations on the activity of early- and later-generation fluoroquinolones requires further investigation and could inform the selection of a fluoroquinolone for treatment.

Global surveillance for drug-resistant tuberculosis (TB) suggests that at least 3.5% of the 9 million incident TB cases are multidrug resistant (MDR), i.e., resistant to isoniazid and rifampin. Fluoroquinolones are among the most effective drugs available for the treatment of MDR TB (1, 2). The importance of the fluoroquinolone drug class is implied in how extensively drug-resistant (XDR) TB is defined, i.e., as MDR TB with additional *in vitro* resistance to second-line injectables and any member of the fluoroquinolone drug class. The different fluoroquinolone agents vary in their potency against *Mycobacterium tuberculosis*, with third- and fourth-generation agents (e.g., levofloxacin, gatifloxacin, and moxifloxacin) having higher activity than second-generation agents (e.g., ciprofloxacin or ofloxacin) (3, 4). These differences have led the World Health Organization (WHO) to recommend against extrapolating *in vitro* culture-based resistance results from second- to later-generation fluoroquinolones and to revise the *in vitro* testing drug concentration upward to 2 mg/liter for moxifloxacin (4, 5). Revisions of drug testing concentrations also highlight the need for quantitative resistance testing with MIC measurements when new diagnostic technologies are being compared to culture-based drug susceptibility tests.

Fluoroquinolones exert their antibacterial activity by inhibiting DNA gyrase and topoisomerase IV, limiting the cell's capacity for DNA replication and transcription. *M. tuberculosis* lacks topoisomerase IV, and its gyrase consists of two subunits encoded by the genes *gyrA* and *gyrB* (6, 7). Mutations in these genes, particularly in the *gyrA* quinolone resistance-determining region (QRDR), are the main cause of fluoroquinolone resistance in *M. tuberculosis* (8). In addition to mutations that confer resistance,

the *gyrA* QRDR also harbors neutral mutations that do not confer resistance (6–9).

Molecular diagnostics for isoniazid and rifampin resistance are now available, with advantages over conventional culture-based drug susceptibility (7, 10, 11). As these tests can be performed directly on sputum, their use does not require the biosafety facilities needed for conventional culture. They can be performed by relatively unskilled workers, and results can be available in 90 min (12). Molecular technique-based diagnostics that detect *gyrA* QRDR mutations have been developed, but the sensitivity for predicting phenotypic fluoroquinolone resistance is highly variable, ranging from 69% to 99% (13). In addition, studies often report aggregate test performance, pooling sensitivity and specificity across early- and later-generation fluoroquinolone agents, and infrequently report on MIC measurements (14). To improve the

Received 15 October 2015 Returned for modification 6 November 2015

Accepted 4 January 2016

Accepted manuscript posted online 13 January 2016

Citation Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M. 2016. Gyrase mutations are associated with variable levels of fluoroquinolone resistance in *Mycobacterium tuberculosis*. J Clin Microbiol 54:727–733. doi:10.1128/JCM.02775-15.

Editor: K. C. Carroll

Address correspondence to Maha R. Farhat, mrfarhat@partners.org.

M.R.F. and K.R.J. contributed equally to this work.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/JCM.02775-15>.

Copyright © 2016, American Society for Microbiology. All Rights Reserved.

accuracy of molecular diagnostics, detailed analyses assessing differential effects of the *gyr* mutations on resistance to early- versus late-generation fluoroquinolones is important, as resistance to the latter more active agents is the increasingly clinically relevant readout. In addition, the identification of more than one mutation in the *gyr* genes in a given isolate is not uncommon, and although there is compelling evidence that these can affect the MIC in laboratory strains (15) and in other bacterial systems (16), the role of mutation additive effects and mutation-mutation interactions (17, 18) in clinical isolates has been rarely reported on. Because the incorporation of any additive and interaction effects can improve the prediction of fluoroquinolone resistance from the *gyr* genotype, we sought to systematically examine these associations in 240 MDR and XDR clinical *M. tuberculosis* isolates. Here, we performed quantitative resistance phenotyping with MIC measurements for both early- and late-generation fluoroquinolones (specifically, ofloxacin and moxifloxacin) and performed targeted sequencing of the entire open reading frames and promoter regions of the *gyr* genes.

MATERIALS AND METHODS

Ethics review. This study was deemed not to constitute human subject research by the Partners Health Care Human Research Committee.

Strain selection and MIC testing. Using an archive of *M. tuberculosis* isolates from patients referred for individualized M/XDR TB treatment in Lima, Peru, between 1 February 1997 and 31 July 2003 (1), we selected isolates that had undergone ciprofloxacin drug susceptibility testing (DST) using the indirect agar proportion method on 7H10 medium (19). In 2001, the testing laboratory altered its standard ciprofloxacin critical concentration, reducing it from 2 mg/liter to 1 mg/liter. We randomly selected 175 ciprofloxacin-resistant and 100 ciprofloxacin-sensitive isolates from this archive for ofloxacin and moxifloxacin MIC testing using the indirect proportion method on 7H10 agar. The concentrations tested were 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/liter of ofloxacin and 0.125, 0.25, 0.5, 1.0, 4.0, and 8.0 mg/liter moxifloxacin for each isolate. At the time these concentrations were chosen, the WHO's revised critical concentration of 2.0 mg/liter for moxifloxacin had not yet been adopted. Colony counts were recorded for the control and for dilutions of 10^{-2} and 10^{-4} at each of the 6 drug concentrations. For quality control, we selected a subset of isolates for repeat MIC testing. The repeat MIC results were retained for all data analysis.

Sequencing. In brief the *gyrA* and *gyrB* gene sequences were captured using molecular inversion probes (MIPs) (20) designed to cover both DNA strands of the open reading frames, promoter regions, and 100 flanking bases on either side of the selected genes (primers are listed in Table S1 in the supplemental material). DNA was extracted from cultures using the cetyltrimethylammonium bromide (CTAB) method (21) without colony selection. Barcodes and Illumina adapters were attached to the captured sequences during the amplification phase to allow for parallel sequencing. We sequenced the amplified targets on an Illumina GAIIX device, producing raw reads of 75 nucleotides. We repeated this process on strains for which fewer than 95% of the targeted nucleotide positions were covered by at least 20 reads, and we retained in the analysis only those resequenced strains that met these criteria. We called mutations using Bowtie (22) 0.12.7/SAMtools (23) 0.1.18 using the thresholds listed in Table S2 in the supplemental material. We excluded any synonymous mutations and the polymorphisms E21Q, T80A, S95T, G247S, and G668D in *gyrA*, as they are either recognized to be neutral variants or are known markers of genetic lineage (13, 24, 25). Mutations in *gyrB* were numbered based on the <http://tuberculist.epfl.ch/quicksearch.php?gene+name=gyrB&submit=Search>, similar to what was reported by Malik et al. (15).

Statistical analyses. We treated the MIC as a continuous variable, as has been done previously (26). For MICs measured at the extremes of the

concentrations tested, we used the agar colony counts to predict the MIC using linear extrapolation ("approximately" function in R v 3.1.3). The extrapolated concentrations were highly similar across different strains. For an ofloxacin MIC of ≤ 1 mg/liter, we used an extrapolated concentration of 0.99 mg/liter; for an ofloxacin MIC of > 10 mg/liter, we used 10.025 mg/liter; for a moxifloxacin MIC of ≤ 0.125 mg/liter, we used 0.12375 mg/liter; and for a moxifloxacin MIC of > 8 mg/liter, we used 8.5 mg/liter. We performed a sensitivity analysis by repeating the univariate and multivariate model construction described below and altering the value assigned to the extreme MICs.

We used the Wilcoxon rank sum test using R version 3.1.3 for univariate association testing of the *gyr* mutation with the MIC. As MIC distributions are recognized to be Gaussian on a 2-fold log scale (27), for the multivariate analysis, we transformed the MIC measures to the \log_2 scale and performed linear regression. All nonsynonymous *gyr* mutations excluding *gyrA* E21Q, T80A, S95T, G247S, and G668D were included in the multivariate model. A multiplicative interaction term was added for each pair of mutations only if two or more strains carried the mutation pair (4 interaction pairs). We applied forward, backward, and bidirectional stepwise selection using the Akaike information criterion (AIC) to arrive at the final model. We performed a generalized linear F test to assess whether coefficients of *gyrA* D94G, A90V, and D94A were equal in the moxifloxacin model. Throughout, we used a *P* value cutoff of 0.01 to assess statistical significance.

We estimated the MIC distribution curves as follows. Using the observed MICs for the pooled isolates harboring either *gyrA* A90V or D94A, we computed a Gaussian kernel density with a standard deviation (bandwidth) of two using the "density" function in R. We computed this separately for each drug.

Fingerprinting and phylogeny construction. Molecular fingerprinting by either spoligotyping or IS6110 restriction fragment length polymorphism (RFLP) analysis was performed for 44 of the isolates using standard methods (28, 29), and lineages were identified by comparison with those from publically available databases (30). For all isolates, data from 28 drug resistance genetic loci, 44,997 kbp, was available from a previous study (M. R. Farhat, S. Razvan, S. Boseman, O. Iartchouk, J. Galagan, P. Sisk, H. Nebenzahl-Guimaraes, K. Jacobson, A. Sloutsky, D. Kaur, J. Posey, B. N. Kreiswirth, N. Kurpina, L. Rigouts, E. M. Streicher, T. C. Victor, R. M. Warren, D. van Soolingen, and M. Murray, submitted for publication). These data, after exclusion of variants presumed to be associated with drug resistance (31), were used to construct and annotate a neighbor-joining tree with the Phylip (32) Neighbor program and Figtree v1.4.0. We also determined the presence or absence of 23 lineage-defining SNPs (33, 34) in these loci (see Table S3 in the supplemental material).

RESULTS

Of the 275 MDR TB isolates, 35 duplicate samples from the same patient were excluded. Among the remaining 240, 76 were previously determined to be ciprofloxacin sensitive and 165 were ciprofloxacin resistant. For quality control, we repeated MIC testing on a randomly selected subset of 20 isolates. Sixteen isolates were reconfirmed to have the exact moxifloxacin and ofloxacin MIC. For two isolates, the measured moxifloxacin MIC increased from 0.250 mg/liter to 0.5 mg/liter. For one, the moxifloxacin MIC changed from ≤ 0.125 to 0.250 mg/liter, and for the last, the moxifloxacin MIC decreased from 8 to 4 and the ofloxacin MIC changed from 8 to 6 mg/liter.

Across the 240 isolates, 96% of the *gyr* gene bases were covered with 20 or more reads, and 88% were covered with more than 100 reads. The isolates were genetically diverse, and both the Euro-African American lineages (LAM, T, H, and X) and the East Asian lineage (Beijing) were represented (see Fig. S1 and Table S3 in the supplemental material).

TABLE 1 Mutations in *gyr* genes by drug and their univariate association *P* value using the Wilcoxon rank sum test^a

Gene	Mutation	Amino acid change	Mutation frequency (of 240)	Ofloxacin ^b			Moxifloxacin ^b		
				Median MIC (IQR)	MIC (min, max)	<i>P</i>	Median MIC (IQR)	MIC (min, max)	<i>P</i>
<i>gyrA</i>	7582AG	D94G	32	6.0 (4.0, 6.0)	<1.0, >10.0	<0.001	4.0 (1.0, 4.0)	0.250, >8.0	<0.001
<i>gyrA</i>	7570CT	A90V	26	4.0 (4.0, 4.0)	<1.0, 10.0	<0.001	1.0 (0.6, 1.0)	<0.125, 8.0	<0.001
<i>gyrB</i>	6052TG	I310M	16	<1.0 (<1.0, 2.5)	<1.0, >10.0	0.7	0.25 (<0.125, 1.0)	<0.125, 8.0	0.7
<i>gyrB</i>	7221GC	S700T	16	<1.0 (<1.0, 2.5)	<1.0, >10.0	0.7	0.25 (<0.125, 1.0)	<0.125, 8.0	0.7
<i>gyrA</i>	7582AC	D94A	14	2.0 (2.0, 4.0)	<1.0, 8.0	0.006	1.0 (0.50, 1.0)	0.250, 4.0	0.02
<i>gyrB</i>	6140GT	V340L	11	4.0 (2.0, 4.0)	<1.0, >10.0	0.01	1.0 (0.8, 4.0)	0.250, 4.0	0.003
<i>gyrA</i>	7581GT	D94Y	5	6.0(4.0, 8.0)	4.0, >10.0	0.001	4.0 (1.0, 8.0)	1.0, 8.0	0.003
<i>gyrB</i>	6735AC	N538T	4	>10 (7.8, >10)	<1.0, >10.0	0.01	8.0 (6.1, 8.0)	0.25, >8.0	0.04
<i>gyrA</i>	7572TC	S91P	3	4.0 (3.0, 4.0)	2.0, 4.0	0.13	4.0 (2.5, 4.0)	1.0, 4.0	0.03
<i>gyrA</i>	7566GA	D89N	3	<1.0 (<1.0, 2.5)	<1.0, 4.0	0.7	4.0 (2.5, 4.0)	1.0, 4.0	0.03
<i>gyrA</i>	7581GA	D94N	2	8.0	6.0, >10.0	0.01	6.1	4.0, >8.0	0.02
<i>gyrA</i>	8101CT	T267I	2	4.0	4.0, 4.0	0.1	1.0	1.0, 1.0	0.2
<i>gyrA</i>	8475CT	R392C	2	3.5	<1.0, 6.0	0.6	2.1	0.250, 4.0	0.4
<i>gyrA</i>	7521GT	A74S	1	<1.0		0.4	1.0		0.4
<i>gyrA</i>	7605CT	P102S	1	4.0		0.3	1.0		0.4
<i>gyrA</i>	7684GA	R128K	1	2.0		0.6	0.5		0.8
<i>gyrA</i>	8164CA	A288D	1	4.0		0.3	1.0		0.4
<i>gyrA</i>	9111CT	P604S	1	<1.0		0.4	<0.125		0.2
<i>gyrB</i>	5354GA	E78K	1	2.0		0.6	<0.125		0.2
<i>gyrB</i>	6479GT	A453S	1	<1.0		0.4	0.250		0.9
<i>gyrB</i>	6575CT	R485C	1	2.0		0.6	<0.125		0.2
<i>gyrB</i>	6576GA	R485H	1	<1.0		0.4	1.0		0.4
<i>gyrB</i>	6579CA	S486Y	1	<1.0		0.4	1.0		0.4
<i>gyrB</i>	6734AG	N538D	1	4.0		0.3	4.0		0.2
<i>gyrB</i>	6737AG	T539A	1	4.0		0.3	0.250		0.9
<i>gyrB</i>	6742AC	E540D	1	<1.0		0.4	4.0		0.2
<i>gyrB</i>	7158AC	D679A	1	<1.0		0.4	<0.125		0.2
<i>gyrB</i>	7163GC	A681P	1	6.0		0.1	4.0		0.2

^a Mutations are ordered by their observed frequency. In bold are QRDR mutations as defined by Tagliani et al. (35). MICs are in milligrams per liter. IQR, interquartile range.

^b Values are for all isolates with the indicated mutation.

We found 37 distinct mutations in the *gyr* genes, all single nucleotide substitutions, 29 (76%) of which were nonsynonymous changes; 15 were located in *gyrA* and 14 were in *gyrB*. We found no variants in the *gyr* promoter region. The mutations most strongly associated with ofloxacin and moxifloxacin resistance on univariate analyses were the *gyrA* D94G, A90V, and D94Y mutations and the *gyrB* V340L and N538T mutations (Table 1). The *gyrA* D94A and A90V mutations were associated with median MICs of 2 and 4 mg/liter, respectively, for ofloxacin and with a median moxifloxacin MIC of 1 mg/liter. We found 17 mutations outside the QRDRs (Table 1).

We estimated the association between MIC and *gyr* mutations and their pairwise interactions through multivariate regression (Table 2). As 31% (35/112) of the isolates with *gyr* mutations harbored more than one mutation (see Table S4 in the supplemental material), the multivariate models allowed us to isolate and compare the effects of each mutation on the moxifloxacin and ofloxacin MICs. Several *gyrA* mutations were associated with a higher MIC of both ofloxacin and moxifloxacin. The *gyrA* D89N mutation, however, was significantly associated with an increase in the moxifloxacin MIC but was not significantly associated with a change in the ofloxacin MIC in both univariate and multivariate analyses.

The *gyrB* mutations N538T, N538D, T539A, E540D, and A681P, although infrequent, were associated with significant effects on the MIC in either the univariate or multivariate analysis

(Table 2). The *gyrB* mutation N538T was the most frequently observed of these mutations, occurring in 4 isolates. Although statistically significant in the univariate analysis, it was no longer significant after adjustment for the presence of other *gyr* mutations; specifically, 3 of the 4 isolates with *gyrB* N538T carried a mutation in codon 94 of *gyrA*. The fourth isolate carried only *gyrB* N538T and had moxifloxacin and ofloxacin MICs of 0.250 and <1 mg/liter, respectively. Notably, all three isolates that carried *gyrB* N538T and *gyrA* codon 94 mutations (1 with D94N and 2 with D94G) had moxifloxacin MICs of ≥ 8 mg/liter and ofloxacin MICs of ≥ 10 mg/liter, whereas the remaining 31 isolates that carried D94N or D94G alone had moxifloxacin MICs of ≤ 4 mg/liter (median, 4 mg/liter) and ofloxacin MICs of ≤ 10 mg/liter (median, 6 mg/liter). Although the interaction term between *gyrB* N538T and *gyrA* D94G was not significant in the multivariate model, including the interaction term improved the models' MIC prediction for both moxifloxacin and ofloxacin. In the multivariate model, the *gyrB* mutations N538D and A681P were associated with significant elevations in MICs of both drugs; *gyrB* E540D was significantly associated with an increase in the MIC of moxifloxacin but not to ofloxacin, and *gyrB* T539A was associated with an increase in ofloxacin MIC but not moxifloxacin MIC. Although the *gyrB* mutation V340L was individually associated with a higher MIC of both drugs, it was not significantly associated with a higher MIC in the multivariate analysis; we observed that 9 of the 11 isolates that carried this mutation also had a mutation in *gyrA* (3

TABLE 2 Linear regression multivariate model results for log₂ transformed MICs^a

Drug, gene, and mutation	Log ₂ MIC change (95% CI)	P
Ofloxacin		
<i>gyrA</i> D94G	1.8 (1.5, 2.1)	<0.0001*
<i>gyrA</i> A90V	1.6 (1.3, 1.9)	<0.0001*
<i>gyrA</i> D94Y	2.4 (1.8, 3.0)	<0.0001*
<i>gyrA</i> D94A	1.1 (0.7, 1.5)	<0.0001*
<i>gyrA</i> D94N	2.7 (1.6, 3.8)	<0.0001*
<i>gyrB</i> A681P	2.4 (1.1, 3.8)	0.0006*
<i>gyrA</i> A288D	1.8 (0.5, 3.2)	0.009*
<i>gyrB</i> T539A	1.8 (0.5, 3.2)	0.009*
<i>gyrB</i> N538D	1.8 (0.5, 3.2)	0.009*
<i>gyrA</i> S91P	0.9 (0.1, 1.7)	0.03
<i>gyrA</i> D94G: <i>gyrB</i> N538T	1.2 (−0.2, 2.7)	0.10
<i>gyrB</i> N538T	0.1 (−1.0, 1.2)	0.83
Moxifloxacin		
<i>gyrA</i> D94G	3.1 (2.7, 3.5)	<0.0001*
<i>gyrA</i> A90V	2.2 (1.7, 2.7)	<0.0001*
<i>gyrA</i> D94Y	4.3 (3.2, 5.4)	<0.0001*
<i>gyrA</i> D89N	3.7 (2.4, 4.9)	<0.0001*
<i>gyrA</i> D94A	1.7 (1.1, 2.3)	<0.0001*
<i>gyrA</i> D94N	4.6 (2.8, 6.3)	<0.0001*
<i>gyrA</i> S91P	2.6 (1.4, 3.9)	0.0001*
<i>gyrB</i> E540D	4.3 (2.2, 6.5)	0.0001*
<i>gyrB</i> A681P	4.3 (2.2, 6.5)	0.0001*
<i>gyrB</i> N538D	4.3 (2.2, 6.5)	0.0001*
<i>gyrB</i> E78K	−2.9 (−5.1, −0.7)	0.01
<i>gyrB</i> V340L	0.8 (0.1, 1.5)	0.04
<i>gyrB</i> S486Y	2.3 (0.1, 4.5)	0.04
<i>gyrA</i> A74S	2.3 (0.1, 4.5)	0.04
<i>gyrB</i> R485H	2.3 (0.1, 4.5)	0.04
<i>gyrA</i> A288D	2.3 (0.1, 4.5)	0.04
<i>gyrA</i> P102S	−2.0 (−4.4, 0.4)	0.11
<i>gyrA</i> D94G <i>gyrB</i> N538T	1.7 (−0.7, 4.1)	0.16
<i>gyrB</i> N538T	0.6 (−1.2, 2.3)	0.54

^a Mutations or their interactions are ordered by their *P* value for each drug. An asterisk indicates significance at the 0.01 threshold. The values represent the increase in log₂ MIC (in milligrams per liter) when the mutation is present versus when it is absent, controlling for the other mutations and interactions listed.

with D94G, 5 with A90V, and 1 with D94A). Forward, backward, and bidirectional stepwise selection all yielded an identical final multivariate model for each drug. In the sensitivity analysis, we confirmed that altering the value assigned to the extreme MICs did not change the final MIC models' coefficients by >10% and did not alter their significance.

Of the *gyrA* QRDR mutations, the mutations A90V and D94A had the smallest effect on the moxifloxacin MIC (log₂ MIC change of 2.2 [95% confidence interval {CI}, 1.7 to 2.7] and 1.7 [95% CI, 1.1 to 2.3], respectively). These effects were statistically different from the effect of *gyrA* D94G, with a 3.1 log₂ MIC change (95% CI, 2.7 to 3.5) (F test *P* values of 0.003 and 0.0005, respectively). For ofloxacin, the mutations A90V and D94A had a comparable effect on the MIC as D94G (F test *P* values of 0.4 and 0.02, respectively). We estimated the ofloxacin and moxifloxacin MIC distribution for isolates with these *gyrA* mutations. The MIC distribution's mode was 0.9 mg/liter for moxifloxacin (Fig. 1) and 3.5 mg/liter for ofloxacin. Only 5/40 (13%) of these isolates would be classified

as resistant to moxifloxacin (MIC > 2 mg/liter), and 27/40 (68%) would be classified as resistant to ofloxacin (MIC > 2 mg/liter).

We determined the percentage of isolates with high moxifloxacin MICs that harbored only *gyrB* mutations. Of 39 isolates with a moxifloxacin MIC of >2 mg/liter, 13 carried a *gyrB* mutation. Only four isolates carried a *gyrB* mutation without a cooccurring QRDR mutation in *gyrA*. Three of the 39 isolates (8%) carried a *gyrB* mutation that was associated with resistance in the multivariate analysis (N538D, A681P, and E540D); the fourth isolate carried the *gyrB* S700T mutation. The *gyrB* mutations N538D, A681P, and E540D did not occur in any isolate with a moxifloxacin MIC of <2 mg/liter.

Isolates with higher MICs were more likely to carry a *gyr* mutation (Fig. 2) and all the isolates within the highest MIC categories (ofloxacin MIC of ≥10 mg/liter, 6 isolates; moxifloxacin MIC of ≥8 mg/liter, 7 isolates) harbored *gyr* mutations. In isolates with intermediate MICs, there were no *gyr* mutations found in 17% (12/71) of isolates for ofloxacin (MIC, 4 to 8 mg/liter) and in 12% (9/77) of isolates for moxifloxacin (MIC, 1 to 4 mg/liter). *gyrA* and *gyrB* individual mutations, excluding *gyrB* I310M, V340L, and S700T, which were not significant by multivariate analysis and interaction effects, have sensitivities of 75% and 90% for predicting moxifloxacin MICs of >0.25 and >2 mg/liter, respectively. The specificity of this set of mutations at the respective moxifloxacin MICs is 90% and 70%. Restricting to the *gyr* QRDR regions tested in version 2.0 of the GenoType MTBDRsl assay (35), the sensitivities are 70% and 87% and the specificities are 93% and 73% for moxifloxacin MICs of >0.25 and >2 mg/liter, respectively.

DISCUSSION

Our data support the conclusion that *gyr* mutations can have differential effects on resistance to early- versus late-generation fluoroquinolones. We found the *gyrA* mutations A90V and D94A to have a smaller effect on the moxifloxacin MIC than the *gyrA* D94G mutation, but we did not observe a similar difference for ofloxacin. Previous studies have also found *gyrA* A90V to have a weaker effect on moxifloxacin resistance, including allelic exchange experiments, where the ofloxacin MIC was found to be in the 2- to 4-mg/liter range and the moxifloxacin MIC was consistently ≤1 mg/liter and sensitive by current WHO standards (36–38). We could not find any experimental or allelic exchange data on the effect of D94A on fluoroquinolone resistance, but this mutation is regarded as a canonical cause for any fluoroquinolone resistance in MTB (38–40). The estimated moxifloxacin MIC distribution for strains carrying either D94A or A90V peaks lower than the expected peak serum concentration (41, 42), suggesting that it may be possible to nevertheless “treat through” this resistance with moxifloxacin but not with ofloxacin (Fig. 1). Studies of dose increases and patient treatment outcome are needed to confirm this.

We also found that *gyrA* D89N and *gyrB* E540D cause differential resistance to moxifloxacin in clinical strains; this is supported by previous allelic exchange experiments for *gyrB* E540D, where resistance to ofloxacin, ciprofloxacin, and levofloxacin was also tested (15). Our data also suggest that interactions between *gyrA* and *gyrB* mutations influence the fluoroquinolone MIC. In particular, isolates harboring both *gyrB* N538T and either *gyrA* D94G or *gyrA* D94N may have higher MICs than isolates carrying the *gyrA* mutations alone. However, we observed these mutation




FIG 1 Estimated ofloxacin (OFX) and moxifloxacin (MXF) MIC distributions in isolates with the *gyrA* mutation A90V or D94A (there were no isolates with both mutations). MIC distributions are superimposed on a histogram of the observed MICs. The MXF MIC peaks lower than the lower limit of the peak MXF serum concentrations (dotted pink line; 3 mg/liter) (41); however, the OFX MIC peaks higher than the peak serum concentration for OFX (dotted blue line; 2 mg/liter) (42).

combinations in a small proportion of isolates, and further analysis in larger data sets and perhaps with allelic exchange is needed to confirm this interaction.

In addition, we found that *gyrB* mutations alone explained 8% of moxifloxacin resistance, and although all the *gyrA* mutations

significantly associated with moxifloxacin resistance were in the QRDR, we found several *gyrA* mutations outside the QRDR in fluoroquinolone-resistant isolates. We found that isolates with intermediate MICs were less likely to carry *gyr* mutations than those in the highest-MIC categories. Potential etiologies of the




FIG 2 Histogram of *gyr* mutation frequency as a function of MIC by drug. MICs are plotted using a \log_2 scale. The two extreme MIC bins were collapsed into the adjacent MIC bin. All nonsynonymous mutations were counted except for the lineage *gyrA* mutations E21Q, T80A, S95T, G247S, and G668D and the *gyrB* mutations I310M, V340L, and S700T, as the latter 3 were not found to be associated with drug resistance in the multivariate model.

unexplained phenotypic resistance in these isolates include the presence of rarer subpopulations of bacilli that carry *gyr* mutations that were not detected despite the high depth of sequencing. Alternatively, other genetic mechanisms, including mutation-mutation interactions outside the *gyr* regions may explain fluoroquinolone resistance in these strains. Alterations in both efflux pump function and the DNA gyrase-associated protein MfpA have been proposed, but neither has been confirmed to be a relevant cause of fluoroquinolone resistance in clinical isolates (13).

Overall, our study highlights the complexity of phenotypic resistance prediction from the *gyr* genotype. Capturing the differential effect of the mutations on early- and later-generation fluoroquinolone agents will require an improved interpretation of the molecular test results, one that is drug specific and perhaps classifies mutations into three or more risk categories for resistance. If future research, especially studies that involve the whole-genome sequences, reveals and confirms the role of mutation-mutation interactions, more complex statistical models of predicting resistance may be required to help improve the genotype sensitivity for predicting the fluoroquinolone resistance phenotype.

ACKNOWLEDGMENTS

We thank the Peruvian team for their patient care and for providing the clinical isolates that made this study possible.

M.R.F. and K.R.J. designed the study with key contributions from C.D.M. and M.M. A.S. and D.K. maintained the strain bank and performed the MIC measurements. M.R.F. performed the data analysis with key input from M.F.F. and wrote the first draft of the manuscript. M.M., C.D.M., M.F.F., and K.R.J. provided key edits of the manuscript.

This work was supported by the Harvard Center for AIDS Research (CFAR), a NIH-funded program supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, NIDDK, NIGMS, FIC, and OAR.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

We declare no conflicts of interest.

FUNDING INFORMATION

Parker B Francis provided funding to Maha Farhat. HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) provided funding to Megan Murray under grant number U19-AI109755. HHS | NIH | Fogarty International Center (FIC) provided funding to Karen Jacobson under grant number K01 TW009213. American Lung Association provided funding to Maha Farhat under grant number RG-270912-N. Harvard University Center for AIDS Research (HU CFAR) provided funding to Maha Farhat and Karen Jacobson under grant number P30 AI060354.

REFERENCES

- Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HSF, Furin JJ, Guerra D, Hurtado RM, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Seung KJ, Shin SS, Sloutsky A, Tolman AW, Becerra MC. 2013. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. *PLoS One* 8:e58664. <http://dx.doi.org/10.1371/journal.pone.0058664>.
- Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. 2007. Fluoroquinolones for the treatment of pulmonary tuberculosis. *Drugs* 67:2077–2099. <http://dx.doi.org/10.2165/00003495-200767140-00007>.
- Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. *Clin Infect Dis* 51:6–14. <http://dx.doi.org/10.1086/653115>.
- Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. 2015. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. *Int J Tuberc Lung Dis* 19:339–341. <http://dx.doi.org/10.5588/ijtld.14.0814>.
- World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.
- Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. *J Antimicrob Chemother* 67:819–831. <http://dx.doi.org/10.1093/jac/dkr566>.
- Hillemann D, Rüscher-Gerdes S, Richter E. 2009. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. *J Clin Microbiol* 47:1767–1772. <http://dx.doi.org/10.1128/JCM.00081-09>.
- Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. *Antimicrob Agents Chemother* 50:104–112. <http://dx.doi.org/10.1128/AAC.50.1.104-112.2006>.
- Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rüscher-Gerdes S, Niemann S. 2009. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multi-drug-resistant tuberculosis patients undergoing treatment. *Antimicrob Agents Chemother* 53:3353–3356. <http://dx.doi.org/10.1128/AAC.00050-09>.
- Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med* 363:1005–1015. <http://dx.doi.org/10.1056/NEJMoa0907847>.
- Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. 2010. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. *J Clin Microbiol* 48:1683–1689. <http://dx.doi.org/10.1128/JCM.01947-09>.
- Small PM, Pai M. 2010. Tuberculosis diagnosis—time for a game change. *N Engl J Med* 363:1070–1071. <http://dx.doi.org/10.1056/NEJMe1008496>.
- Miotto P, Cirillo DM, Migliori GB. 2015. Drug resistance in Mycobacterium tuberculosis: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness. *Chest* 147:1135–1143. <http://dx.doi.org/10.1378/chest.14-1286>.
- Molina-Moya B, Lacombe A, Prat C, Pimkina E, Diaz J, García-Sierra N, Haba L, Maldonado J, Samper S, Ruiz-Manzano J, Ausina V, Dominguez J. 2015. Diagnostic accuracy study of multiplex PCR for detecting tuberculosis drug resistance. *J Infect* 71:220–230. <http://dx.doi.org/10.1016/j.jinf.2015.03.011>.
- Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of *gyrA* and *gyrB* mutations. *PLoS One* 7:e39754. <http://dx.doi.org/10.1371/journal.pone.0039754>.
- Kryazhimskiy S, Rice DP, Jerison ER, Desai MM. 2014. Global epistasis makes adaptation predictable despite sequence-level stochasticity. *Science* 344:1519–1522. <http://dx.doi.org/10.1126/science.1250939>.
- Phillips PC. 2008. Epistasis—the essential role of gene interactions in the structure and evolution of genetic systems. *Nat Rev Genet* 9:855–867. <http://dx.doi.org/10.1038/nrg2452>.
- Woods RJ, Barrick JE, Cooper TF, Shrestha U, Kauth MR, Lenski RE. 2011. Second-order selection for evolvability in a large Escherichia coli population. *Science* 331:1433–1436. <http://dx.doi.org/10.1126/science.1198914>.
- CLSI document M24-A. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard. CLSI, Wayne, PA.
- Hardenbol P, Banér J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, Fakhrai-Rad H, Ronaghi M, Willis TD, Landegren U, Davis RW. 2003. Multiplexed genotyping with sequence-tagged molecular inversion probes. *Nat Biotechnol* 21:673–678. <http://dx.doi.org/10.1038/nbt821>.
- Parish T, Brown AC. 2009. Mycobacteria protocols, 2nd ed. Humana Press, Totowa, NJ.
- Langmead B. 2010. Aligning short sequencing reads with Bowtie. *Curr*

- Protoc Bioinformatics Chapter 11:Unit 11.7. <http://dx.doi.org/10.1002/0471250953.bi1107s32>.
23. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The sequence alignment/map format and SAMtools. *Bioinformatics* 25:2078–2079. <http://dx.doi.org/10.1093/bioinformatics/btp352>.
 24. Lau RWT, Ho P-L, Kao RYT, Yew W-W, Lau TCK, Cheng VCC, Yuen K-Y, Tsui SKW, Chen X, Yam W-C. 2011. Molecular characterization of fluoroquinolone resistance in *Mycobacterium tuberculosis*: functional analysis of *gyrA* mutation at position 74. *Antimicrob Agents Chemother* 55:608–614. <http://dx.doi.org/10.1128/AAC.00920-10>.
 25. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias CA, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CLC, Bowden R, Drobniowski FA, Allix-Béguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TEA, Modernizing Medical Microbiology (MMM) Informatics Group. 2015. Whole-genome sequencing for prediction of *Mycobacterium tuberculosis* drug susceptibility and resistance: a retrospective cohort study. *Lancet Infect Dis* 15:1193–1202. [http://dx.doi.org/10.1016/S1473-3099\(15\)00062-6](http://dx.doi.org/10.1016/S1473-3099(15)00062-6).
 26. Sherrard LJ, Schaible B, Graham KA, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, Muhlebach MS, Gilpin DF, Schneiders T, Elborn JS, Tunney MM. 2014. Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in *Prevotella* isolated from cystic fibrosis (CF) and non-CF patients. *J Antimicrob Chemother* 69:2690–2698. <http://dx.doi.org/10.1093/jac/dku192>.
 27. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. *Clin Microbiol Infect* 12:418–425. <http://dx.doi.org/10.1111/j.1469-0691.2006.01377.x>.
 28. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. *J Clin Microbiol* 35:907–914.
 29. van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. 1991. Occurrence and stability of insertion sequences in *Mycobacterium tuberculosis* complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. *J Clin Microbiol* 29:2578–2586.
 30. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajj SA, Allix C, Aristimuño L, Arora J, Baumanis V, Binder L, Cafrune P, Cataldi A, Cheong S, Diel R, Ellermeier C, Evans JT, Fauville-Dufaux M, Ferdinand S, de Viedma DG, Garzelli C, Gazzola L, Gomes HM, Guttierrez MC, Hawkey PM, van Helden PD, Kadival GV, Kreiswirth BN, Kremer K, Kubin M, Kulkarni SP, Liens B, Lillebaek T, Ly HM, Martin C, Martin C, Mokrousov I, Narvskaja O, Ngeow YF, Naumann L, Niemann S, Parwati I, Rahim Z, Rasolof-Razanamparany V, Rasolonavalona T, Rossetti ML, Rüschi-Gerdes S, Sajduda A, Samper S, Shemyakin IG, Singh UB, Somoskovi A, Skuce RA, van Soolingen D, Streicher EM, Suffys PN, Tortoli E, Tracevska T, Vincent V, Victor TC, Warren RM, Yap SF, Zaman K, Portaels F, Rastogi N, Sola C. 2006. *Mycobacterium tuberculosis* complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. *BMC Microbiol* 6:23. <http://dx.doi.org/10.1186/1471-2180-6-23>.
 31. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. *PLoS Med* 6:e2. <http://dx.doi.org/10.1371/journal.pmed.1000002>.
 32. Felsenstein J. 1989. PHYLIP—phylogeny inference package (version 3.2). *Cladistics* 5:164–166.
 33. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, Viveiros M, Portugal I, Pain A, Martin N, Clark TG. 2014. A robust SNP barcode for typing *Mycobacterium tuberculosis* complex strains. *Nat Commun* 5:4812. <http://dx.doi.org/10.1038/ncomms5812>.
 34. Feuerriegel S, Köser CU, Niemann S. 2014. Phylogenetic polymorphisms in antibiotic resistance genes of the *Mycobacterium tuberculosis* complex. *J Antimicrob Chemother* 69:1205–1210. <http://dx.doi.org/10.1093/jac/dkt535>.
 35. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjö M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM. 2015. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. *J Clin Microbiol* 53:2961–2969. <http://dx.doi.org/10.1128/JCM.01257-15>.
 36. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. 2014. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 69:331–342. <http://dx.doi.org/10.1093/jac/dkt358>.
 37. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. 2012. *gyrA* mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 67:1088–1093. <http://dx.doi.org/10.1093/jac/dks033>.
 38. Li J, Gao X, Luo T, Wu J, Sun G, Liu Q, Jiang Y, Zhang Y, Mei J, Gao Q. 2014. Association of *gyrA/B* mutations and resistance levels to fluoroquinolones in clinical isolates of *Mycobacterium tuberculosis*. *Emerg Microbes Infect* 3:e19. <http://dx.doi.org/10.1038/emi.2014.21>.
 39. Chakravorty S, Aladegebami B, Thoms K, Lee JS, Lee EG, Rajan V, Cho E-J, Kim H, Kwak H, Kurepina N, Cho S-N, Kreiswirth B, Via LE, Barry CE, Alland D. 2011. Rapid detection of fluoroquinolone-resistant and heteroresistant *Mycobacterium tuberculosis* by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. *J Clin Microbiol* 49:932–940. <http://dx.doi.org/10.1128/JCM.02271-10>.
 40. Chen J, Chen Z, Li Y, Xia W, Chen X, Chen T, Zhou L, Xu B, Xu S. 2012. Characterization of *gyrA* and *gyrB* mutations and fluoroquinolone resistance in *Mycobacterium tuberculosis* clinical isolates from Hubei Province, China. *Braz J Infect Dis* 16:136–141. [http://dx.doi.org/10.1016/S1413-8670\(12\)70294-5](http://dx.doi.org/10.1016/S1413-8670(12)70294-5).
 41. Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. *Antimicrob Agents Chemother* 52:852–857. <http://dx.doi.org/10.1128/AAC.01036-07>.
 42. Böttger EC. 2011. The ins and outs of *Mycobacterium tuberculosis* drug susceptibility testing. *Clin Microbiol Infect* 17:1128–1134. <http://dx.doi.org/10.1111/j.1469-0691.2011.03551.x>.